Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds



Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *